Taken together, the combination of oxaliplatin and LAT1 inhibitor (JPH203) significantly enhanced the therapeutic effect of RCC tumors, which provides a potential solution for chemotherapy resistance for solid tumor. The gene discussed is SLC7A5; the disease is renal cell carcinoma.